Shares of Esperion Therapeutics (NASDAQ:ESPR) have received an average rating of “Buy” from the sixteen research firms that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $92.54.
A number of research analysts recently commented on ESPR shares. BidaskClub lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. Chardan Capital upped their target price on Esperion Therapeutics from $75.00 to $100.00 and gave the company a “neutral” rating in a research note on Tuesday, March 27th. JMP Securities upped their target price on Esperion Therapeutics from $60.00 to $153.00 and gave the company an “outperform” rating in a research note on Thursday, March 8th. Stifel Nicolaus set a $105.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a research note on Monday, January 15th. Finally, Credit Suisse Group started coverage on Esperion Therapeutics in a research note on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price objective for the company.
Shares of ESPR stock traded up $1.37 during trading hours on Thursday, reaching $75.86. 193,347 shares of the company’s stock were exchanged, compared to its average volume of 621,509. Esperion Therapeutics has a fifty-two week low of $30.95 and a fifty-two week high of $82.68. The firm has a market cap of $2,006.53, a PE ratio of -10.72 and a beta of 2.51.
In other news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $71.79, for a total transaction of $838,076.46. Following the sale, the director now owns 3,177 shares in the company, valued at $228,076.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roger S. Newton sold 25,000 shares of the stock in a transaction on Thursday, March 29th. The stock was sold at an average price of $72.37, for a total value of $1,809,250.00. Following the sale, the director now owns 639,682 shares in the company, valued at approximately $46,293,786.34. The disclosure for this sale can be found here. Corporate insiders own 32.50% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. bought a new position in Esperion Therapeutics in the fourth quarter valued at about $222,000. BB&T Securities LLC bought a new position in Esperion Therapeutics in the fourth quarter valued at about $263,000. First Mercantile Trust Co. boosted its holdings in Esperion Therapeutics by 56.0% in the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 1,519 shares during the last quarter. Creative Planning bought a new position in Esperion Therapeutics in the fourth quarter valued at about $314,000. Finally, Oakmont Partners LLC bought a new position in Esperion Therapeutics in the fourth quarter valued at about $323,000. Institutional investors own 91.66% of the company’s stock.
WARNING: This report was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.chaffeybreeze.com/2018/04/17/esperion-therapeutics-espr-receives-consensus-recommendation-of-buy-from-analysts.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.